1-4 of 4
Aaron Gerds
Close
Sort by
Journal Articles

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

Clinical Trials & Observations
Srdan Verstovsek, Ruben Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, Marek Hus, Blanca Xicoy, Stephen T. Oh, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Aaron Gerds, Miklos Egyed, Jiří Mayer, Tomasz Sacha, Jun Kawashima, Marc Morris, Mei Huang, Claire Harrison
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3582–3591.
https://doi.org/10.1182/bloodadvances.2022009311
Published: 2023
Includes: Supplemental data
Journal Articles

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study

Clinical Trials & Observations
John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron Gerds, Vikas Gupta, Brian Higgins, Kathrin Wonde, Candice Jamois, Bruno Kovic, Ling-Yuh Huw, Sudhakar Katakam, Margherita Maffioli, Ruben Mesa, Jeanne Palmer, Marta Bellini, David M. Ross, Alessandro M. Vannucchi, Abdulraheem Yacoub
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1162–1174.
https://doi.org/10.1182/bloodadvances.2021006043
Published: 2022
Includes: Supplemental data
Journal Articles

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

Clinical Trials & Observations
John O. Mascarenhas, Raajit K. Rampal, Heidi E. Kosiorek, Rupali Bhave, Elizabeth Hexner, Eunice S. Wang, Aaron Gerds, Camille N. Abboud, Marina Kremyanskaya, Dimitry Berenzon, Olatoyosi Odenike, Noushin Farnoud, Aishwarya Krishnan, Rona Singer Weinberg, Erin McGovern, Mohamed E. Salama, Vesna Najfeld, Juan S. Medina-Martinez, Juan E. Arango Ossa, Max F. Levine, Yangyu Zhou, Lonette Sandy, Mark L. Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5246–5256.
https://doi.org/10.1182/bloodadvances.2020002119
Published: 2020
Includes: Supplemental data
Journal Articles

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Clinical Trials & Observations
Caner Saygin, Ashwin Kishtagari, Ryan D. Cassaday, Natalie Reizine, Ilana Yurkiewicz, Michaela Liedtke, Wendy Stock, Richard A. Larson, Ross L. Levine, Martin S. Tallman, Jae H. Park, Cassandra Kerr, Bartlomiej Przychodzen, Mikkael A. Sekeres, Matt E. Kalaycio, Hetty E. Carraway, Betty K. Hamilton, Ronald Sobecks, Aaron Gerds, Sudipto Mukherjee, Aziz Nazha, Jaroslaw P. Maciejewski, Anjali S. Advani
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4228–4237.
https://doi.org/10.1182/bloodadvances.2019000925
Published: 2019
Includes: Supplemental data